# An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH

> **NCT07528235** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Intracerebral Hemorrhage
- Stroke-Associated Pneumonia (SAP)

## Interventions

- **DRUG:** Intravenous Pump-Delivered Propranolol

## Key facts

- **NCT ID:** NCT07528235
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07528235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07528235, "An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07528235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*